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During last decades a considerable attempt has been made to 
prevent cardiovascular disease (CVD). Nevertheless, CVD 
remains a leading cause of death world wide [1]. The guide-
lines of medical scientific societies for primary and secon-
dary prevention of CVD are directed towards established 
CVD risk factors (dyslipidemia, diabetes mellitus, hyperten-
sion, obesity, smoking and others). As far as dyslipidemia is 
concerned, the first priority, according to the guidelines [2], 
is to achieve optimal low density lipoprotein cholesterol 
(LDL-C) levels. Many clinical trials have shown that hypol-
ipidemic treatment besides lowering LDL-C also signifi-
cantly reduces CVD-related morbidity and mortality [3, 4]. 
Nevertheless, a considerable number of treated subjects still 
have CVD events. Thus, the need for additional therapeutic 
treatment such as increasing high density lipoprotein choles-
terol (HDL-C) levels and decreasing levels of triglycerides 
(TG) has been suggested [5]. In this context, torcetrapib, an 
inhibitor of cholesteryl ester transport protein (CETP),   
increased HDL-C levels and decreased LDL-C levels [6-8]. 
However, the drug was withdrawn due to side effects.  
Another potential target to reduce CVD risk is postprandial 
hypertriglyceridemia [9, 10]. In 1979, Zilversmit [11]   
proposed that TG are involved in development of atheroscle-
rosis. Since then, many research teams, including ours, [12-
15] have examined
 the role of the exaggerated and delayed 
clearance of postprandial lipoprotein particles in various 
diseases [16, 17] including CVD. The mechanisms involved 
in postprandial lipemia were reviewed [18]. Considering all 
the above, the ideal gene associated with all 3 (TG, HDL and 
postprandial hypertriglyceridemia) is the one encoding for 
CETP.  
The mechanisms by which the CETP controls lipid metabo-
lism have attracted many investigators, especially when 
plasma CETP concentration was found to be associated with 
the increased risk for premature atherosclerosis [19]. CETP 
activity depends on several factors such as environmental 
components (e.g. diet [20], alcohol consumption [21]   
and smoking [22]) gender [23] and genetic influence   
(e.g. polymorphisms of CETP) [24-26].  
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Few months ago, Salerno et al. examined the association 
between CETP and postprandial hypertriglyceridemia in 
transgenic mice [27]. They performed functional studies   
to show that plasma CETP activity modifies postprandial 
response of TG-rich lipoproteins. They assessed the TG   
response to fat load in rats with introduced human CETP 
gene (mice and rats are naturally CETP deficient). They 
found that elevated levels of CETP were associated with fat 
intolerance.  
Genetically, engineered mice have proven to be valid models 
for the study of CETP function and its relation with athero-
sclerosis. Introduction of the human CETP gene into mice 
results in a dose-related reduction of HDL-C levels and, as a 
consequence, these animals have significantly more early 
atherosclerotic lesions in the proximal aorta than control 
mice [28]. CETP variants have a strong impact on CETP 
activity and thus on HDL-C levels [29]. Several polymor-
phisms have been identified in the coding sequence of the 
CETP gene including I405V [30]. The I405V polymorphism 
has been associated with reduced CETP mass, increased 
HDL-C levels and increased CVD risk [31, 32]. Another 
widely studied CETP polymorphism is TaqIB which seems 
to influence HDL-C levels [33]. In normolipidemic subjects, 
the absence of the TaqIB restriction site (B2 allele) is associ-
ated with decreased CETP activity, increased HDL-C levels 
and reduced risk of CVD in males compared with B1 sub-
jects [19]. The CETP TaqIB polymorphism has been found 
to account for 5.8% of the variance in HDL-C, which is im-
portant since the 1 mg/dl increase of HDL-C leads to 2% 
decrease in CVD risk [33, 34]. Subjects with the B2 allele 
usually have lower levels of CETP, higher levels of HDL-C 
and reduced risk of CHD compared with B1 subjects [33]. 
Our group also analyzed the association between TaqIB 
polymorphism and fasting as well as postprandial TG levels 
in heterozygote familial hypercholesterolemia (hFH) patients 
[35]. The B1 allele carriers with exaggerate TG response   
to fat loading had higher fasting and postprandial TGs   
compared with B2 allele carriers. Also, patients with   
the B1B2 genotype had significantly higher HDL-C levels 
compared with the B1B1 genotype. Noone et al. found that 
B1 allele carriers had increased mass and activity of CETP at 
6 h after fat loading compared with B2 allele carriers [36]. 
This finding is similar to our results (higher TG 6 and 8 h 
after fat loading in B1 allele carriers compared with B2; The Link Between Human and Transgenic Animal Studies Involving  The Open Cardiovascular Medicine Journal, 2009, Volume 3    49 
p<0.05 and p<0.042, respectively). This was in accordance 
with other studies as well. Tall et al. found a 1.1–1.7-fold 
increase in CETP in response to a 135-g fat meal [37]. It has 
been shown by others [38, 39] and by us that carriers of the 
B1 allele have a more atherogenic fasting and non fasting 
lipid profile (low HDL-C, increased TGs, exaggerated and 
delayed clearance of TGs postprandially) than carriers of the 
B2 allele, which should lead to increased cardiovascular risk. 
Furthermore, Hogue et al. reported that a high plasma CETP 
concentration was associated with higher risk of having 
small-diameter particles of LDL in hFH patients, suggesting 
that CETP-induced remodeling of LDL is dependent on the 
number of TG-rich lipoproteins [40]. Also, in a previous 
study of ours [41] a significant gender association between 
TG response after oral fat loading and TaqIB polymorphism 
of the CETP gene in subjects with a exaggerate response was 
found. Specifically, men carrying the B2 allele of the TaqIB 
polymorphism showed a higher postprandial TG peak and a 
delayed return to baseline values compared with women   
carrying the B2 allele. The mechanisms of this observation 
were explained by Salerno et al. [27]. They reported that 
CETP expression in transgenic mice delays plasma clearance 
and liver uptake of TG-rich lipoproteins firstly, by transfer-
ring TGs to HDLs and increasing cholesteryl ester concen-
tration of the remnant particles, and secondly by decreasing 
lipoprotein lipase (LPL) expression. Similarly, Zhou et al. 
[42] also found that adipocytes from adipose tissue of trans-
genic mice (CETP expressing) presented reduced LPL   
expression. The mechanisms underlying the differential   
lipemic responses confirmed in CETP expressing and non-
expressing transgenic animals could also be applicable for 
humans expressing high or low CETP activities. Thus, the 
human studies performed by our group presented similar 
positive associations between CETP and TG levels [35]. 
Two other studies have also shown similar results [43, 44].  
A new aspect linked to the effects of CETP expression con-
tribute to a better understanding of the influence of a precise 
gene on lipids and lipoproteins responsiveness to nutritional 
fat. This research carried out in either humans or transgenic 
animals may have clinical implications in the near future. 
The understanding of postprandial lipemia is important, 
since postprandial hypertriglyceridemia is involved in   
endothelial dysfunction, oxidative stress, small dense LDL 
and small dense HDL particles [45]. 
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